ACUTE MYELOID LEUKEMIA (AML)

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This study looked at how adults with a specific type of acute myeloid leukemia (AML) who cannot receive standard chemotherapy feel and function while taking a combination of ivosidenib and azacitidine. The main goal was to measure quality of life using questionnaires, along with …

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers trac…

This study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the…

This study tested whether adding the drug venetoclax to a low-dose chemotherapy (LDAC) helps people with acute myeloid leukemia (AML) live longer. It included 211 adults aged 75+ or 18–74 with health issues that prevent them from receiving strong chemotherapy. The main goal was t…

This phase 3 study tested a new drug, gilteritinib, combined with azacitidine for people with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The participants were adults who could not receive standard intensive chemotherapy. The study compared the combi…

This completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…

This study observed 113 adults in Italy with acute myeloid leukemia (AML) linked to prior cancer therapy or bone marrow problems. All participants received Vyxeos liposomal as part of their normal care. Researchers tracked how many achieved complete remission without detectable d…

This completed study looked at 98 adults with acute myeloid leukemia (AML) in first remission who received a stem cell transplant from a matched sibling, matched unrelated, or half-matched family donor. All patients got the same chemotherapy conditioning before transplant. Resear…